Abstract
BackgroundNot only the prevalence, but also the progress of metabolic abnormalities in schizophrenic patients is of importance for treatment planning and policy making. However, there have been very few prospective studies of metabolic disturbance in schizophrenic patients. This study aimed to assess the progress of metabolic abnormalities in Thai individuals with schizophrenia by estimating their one-year incidence rate of metabolic syndrome (MetS).MethodsWe screened all schizophrenic patients who visited our psychiatric clinic. After the exclusion of participants with MetS at baseline, each subject was reassessed at 6 and 12 months to determine the occurrence of MetS. The definition of MetS, as proposed by the International Diabetes Federation (IDF), was applied.ResultsFifty-seven participants (24 males and 33 females) had a mean of age and duration of antipsychotic treatment of 37.5 years old and 8.4 years, respectively. At baseline, 13 subjects met the MetS definition. Of 44 subjects who had no MetS at baseline, 35 could be followed up. Seven of these 35 subjects (20.0%) had developed MetS at the 6- or 12-month visit, after already having 2 MetS components at baseline. The demographic data and characteristics of those developing and not developing MetS were not different in any respect.ConclusionThai schizophrenic patients are likely to develop MetS. Their metabolic abnormalities may progress rapidly and fulfill the MetS definition within a year of follow-up. These findings support the importance of assessing and monitoring metabolic syndrome in schizophrenic patients.
Highlights
The prevalence, and the progress of metabolic abnormalities in schizophrenic patients is of importance for treatment planning and policy making
During the last several years, there has been a growing interest in metabolic abnormalities in the general population and schizophrenic patients. These disturbances are highly coincident and called metabolic syndrome (MetS), which is a cluster of risk factors for cardiovascular disease comprising central obesity, dyslipidemia, hypertension, and elevated fasting plasma glucose (FPG) level
The widely accepted ones are those proposed by i) National Cholesterol Education Program Adult Treatment Panel III (ATP III) [2]; ii) American Heart Association/National Heart, Lung, and Blood Institute, AHA/NHLBI [3]; and iii) International Diabetes Federation (IDF) [4]
Summary
The progress of metabolic abnormalities in schizophrenic patients is of importance for treatment planning and policy making. During the last several years, there has been a growing interest in metabolic abnormalities in the general population and schizophrenic patients These disturbances are highly coincident and called metabolic syndrome (MetS), which is a cluster of risk factors for cardiovascular disease comprising central obesity, dyslipidemia, hypertension, and elevated fasting plasma glucose (FPG) level. While the updated ATP III definition requires any three of five criteria for a diagnosis, the IDF definition needs central obesity plus any other two abnormalities. Despite this difference, updated ATP III and IDF criteria still identify essentially the same individuals as having MetS. Recommendations for clinical management are virtually identical in the updated ATP III and IDF reports [3]
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
